SK Biopharmaceuticals Co., Ltd.
326030
Rank in Stocks
#3971
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Share Price
$52.48
Market Cap
$4.11B
Change (1 day)
3.55%
Change (1 year)
-26.12%
Country
KR
Trade SK Biopharmaceuticals Co., Ltd. (326030)
Category
Healthcare
Operating Margin for SK Biopharmaceuticals Co., Ltd. (326030)
Operating Margin as of October 2026 TTM: 35.20%
According to SK Biopharmaceuticals Co., Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 35.20%. At the end of 2024 the company had an Operating Margin of 17.59%.
Operating Margin history for SK Biopharmaceuticals Co., Ltd. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 35.20% | 21.97% |
| 2025 | 28.86% | 64.07% |
| 2024 | 17.59% | -266.41% |
| 2023 | -10.57% | -80.15% |
| 2022 | -53.24% | -400.11% |
| 2021 | 17.74% | -101.93% |
| 2020 | -921.18% | 1,339.57% |
| 2019 | -63.99% | -99.49% |
| 2018 | -12,660.28% | 10,924.28% |
| 2017 | -114.84% | 79.07% |
| 2016 | -64.13% | 16.11% |
| 2015 | -55.23% | 1.96% |
| 2014 | -54.17% | -25.84% |
| 2013 | -73.04% | 5.12% |
| 2012 | -69.48% | 7.57% |
| 2011 | -64.59% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -98.90% |
US
|
|
| -149.01% | -104.23% |
US
|
|
| 25.57% | -99.27% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.18% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.